Assessment of interactions and dosage recommendations of synthetic DMARDs—Evidence-based and consensus-based recommendations based on a systematic literature search
Conventional synthetic (cs) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) have potential interactions with a multitude of drugs. Furthermore, they sometimes have a lower therapeutic index, particularly in cases of limited organ functions. The aim of this work was to estab...
Saved in:
Published in | Zeitschrift für Rheumatologie Vol. 83; no. Suppl 1; pp. 8 - 19 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Heidelberg
Springer Medizin
01.02.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Conventional synthetic (cs) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) have potential interactions with a multitude of drugs. Furthermore, they sometimes have a lower therapeutic index, particularly in cases of limited organ functions. The aim of this work was to establish evidence-based recommendations on the therapeutic use of DMARDs in the context of drug interactions and dosage recommendations. A systematic literature search was carried out on the issue of drug interactions and dosages in cases of patients with limited kidney function and higher age and suffering from rheumatoid arthritis. A total of 2756 scientific publications were screened and 154 selected of which 68 were scrutinized in detail. Furthermore, the respective product information was also analyzed. A multitude of possible interactions of synthetic DMARDs with different drugs were detected, which were then assessed with respect to the clinical significance and consequences. A consensus process led to making recommendations with which the interactions were classified: A: dangerous combination, B: avoid combination (if possible, pausing DMARD treatment), C: possible combination requiring increased monitoring and potential adjustments in dosage and D: pharmacological interaction without relevance in DMARD standard doses. Apart from that dosage recommendations were established for each csDMARD and tsDMARD depending on kidney function and age. There are 3 primary recommendations and 11 core recommendations on interactions and dosages of csDMARDs and tsDMARDs meant as a practical help for therapeutic decision making and to improve safety in the treatment of rheumatoid arthritis. |
---|---|
AbstractList | Conventional synthetic (cs) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) have potential interactions with a multitude of drugs. Furthermore, they sometimes have a lower therapeutic index, particularly in cases of limited organ functions. The aim of this work was to establish evidence-based recommendations on the therapeutic use of DMARDs in the context of drug interactions and dosage recommendations. A systematic literature search was carried out on the issue of drug interactions and dosages in cases of patients with limited kidney function and higher age and suffering from rheumatoid arthritis. A total of 2756 scientific publications were screened and 154 selected of which 68 were scrutinized in detail. Furthermore, the respective product information was also analyzed. A multitude of possible interactions of synthetic DMARDs with different drugs were detected, which were then assessed with respect to the clinical significance and consequences. A consensus process led to making recommendations with which the interactions were classified: A: dangerous combination, B: avoid combination (if possible, pausing DMARD treatment), C: possible combination requiring increased monitoring and potential adjustments in dosage and D: pharmacological interaction without relevance in DMARD standard doses. Apart from that dosage recommendations were established for each csDMARD and tsDMARD depending on kidney function and age. There are 3 primary recommendations and 11 core recommendations on interactions and dosages of csDMARDs and tsDMARDs meant as a practical help for therapeutic decision making and to improve safety in the treatment of rheumatoid arthritis. Conventional synthetic (cs) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) have potential interactions with a multitude of drugs. Furthermore, they sometimes have a lower therapeutic index, particularly in cases of limited organ functions. The aim of this work was to establish evidence-based recommendations on the therapeutic use of DMARDs in the context of drug interactions and dosage recommendations. A systematic literature search was carried out on the issue of drug interactions and dosages in cases of patients with limited kidney function and higher age and suffering from rheumatoid arthritis. A total of 2756 scientific publications were screened and 154 selected of which 68 were scrutinized in detail. Furthermore, the respective product information was also analyzed. A multitude of possible interactions of synthetic DMARDs with different drugs were detected, which were then assessed with respect to the clinical significance and consequences. A consensus process led to making recommendations with which the interactions were classified: A: dangerous combination, B: avoid combination (if possible, pausing DMARD treatment), C: possible combination requiring increased monitoring and potential adjustments in dosage and D: pharmacological interaction without relevance in DMARD standard doses. Apart from that dosage recommendations were established for each csDMARD and tsDMARD depending on kidney function and age. There are 3 primary recommendations and 11 core recommendations on interactions and dosages of csDMARDs and tsDMARDs meant as a practical help for therapeutic decision making and to improve safety in the treatment of rheumatoid arthritis.Conventional synthetic (cs) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) have potential interactions with a multitude of drugs. Furthermore, they sometimes have a lower therapeutic index, particularly in cases of limited organ functions. The aim of this work was to establish evidence-based recommendations on the therapeutic use of DMARDs in the context of drug interactions and dosage recommendations. A systematic literature search was carried out on the issue of drug interactions and dosages in cases of patients with limited kidney function and higher age and suffering from rheumatoid arthritis. A total of 2756 scientific publications were screened and 154 selected of which 68 were scrutinized in detail. Furthermore, the respective product information was also analyzed. A multitude of possible interactions of synthetic DMARDs with different drugs were detected, which were then assessed with respect to the clinical significance and consequences. A consensus process led to making recommendations with which the interactions were classified: A: dangerous combination, B: avoid combination (if possible, pausing DMARD treatment), C: possible combination requiring increased monitoring and potential adjustments in dosage and D: pharmacological interaction without relevance in DMARD standard doses. Apart from that dosage recommendations were established for each csDMARD and tsDMARD depending on kidney function and age. There are 3 primary recommendations and 11 core recommendations on interactions and dosages of csDMARDs and tsDMARDs meant as a practical help for therapeutic decision making and to improve safety in the treatment of rheumatoid arthritis. |
Author | Krüger, K. Weseloh, C. Leipe, J. Fiehn, C. Bergner, R. |
Author_xml | – sequence: 1 givenname: C. surname: Fiehn fullname: Fiehn, C. email: c.fiehn@rheuma-badenbaden.de organization: Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Tätigkeitsschwerpunkt klinische Immunologie, Rheumatologie Baden-Baden – sequence: 2 givenname: J. surname: Leipe fullname: Leipe, J. organization: Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), V. Medizinische Klinik, Universitätsmedizin Mannheim – sequence: 3 givenname: C. surname: Weseloh fullname: Weseloh, C. organization: Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Gesellschaft für Rheumatologie (DGRh) – sequence: 4 givenname: R. surname: Bergner fullname: Bergner, R. organization: Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Medizinische Klinik A, Klinikum Ludwigshafen – sequence: 5 givenname: K. surname: Krüger fullname: Krüger, K. organization: Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Rheumatologisches Praxiszentrum St. Bonifatius |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37831190$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUFO3DAUhq0KVAbaC3RRZdlNqB0nE2c5gqFUokJC7dp6cZ4haGKDn4M0Ow7BAdhxjx6Fk-AhUxYsurAsvff9n2z9-2zHeYeMfRH8UHBefyfOZSNzXqQjSlHn8gObiVJWuSgqvsNmXJY8F6qq9tg-0TVP1LwsP7I9WSspRMNn7GlBhEQDuph5m_UuYgATe-8oA9dlnSe4xCyg8UOCOphWCaW1i1cYe5Md_1pcHNPz_cPyru_QGcxbIOxe8ybR6Gik7ey9aJp6l8HfR1pTxAE2ylW_eUccA2aEEMzVJ7ZrYUX4eXsfsD8ny99Hp_nZ-Y-fR4uz3BSNirlqlYEKwFZK1rawtsE5oAQw0siOq8paCdgCt8IK3vBOmRoRVVuVFkAV8oB9m7w3wd-OSFEPPRlcrcChH0kXqq6laup5k9BiQk3wRAGtvgn9AGGtBdebgvRUkE4F6deCtEyhr1v_2A7YvUX-NZIAOQGUVu4Sg772Y3Dpz__TvgAURKVR |
Cites_doi | 10.1007/s10067-013-2389-x 10.1136/bmj.325.7376.1333 10.1136/ard.2006.066761 10.1177/1060028019839650 10.2174/1872312810666151223103353 10.1007/s00393-020-00751-0 10.1177/0091270009338939 10.1111/bcpt.13310 10.1345/aph.1A127 10.1093/rheumatology/keh685 10.3899/jrheum.201248 10.1016/j.semarthrit.2011.06.005 10.1002/cpdd.270 10.1177/003693307301800203 10.3899/jrheum.160818 10.3109/03009742.2013.868511 10.1007/s10067-018-4005-6 10.1007/s40264-020-00938-z 10.1007/s40265-020-01439-0 10.1136/ard.57.2.110 10.1002/pds.4555 10.1007/s10067-012-2122-1 10.1177/0961203396005001041 10.1111/cts.12486 10.1007/s40262-016-0419-y 10.1007/s40265-018-0908-4 10.1002/cpdd.1015 10.1111/bcp.15239 10.1136/ard.2002.004598 10.1136/annrheumdis-2015-eular.1627 10.1002/cpt1976204387 10.1007/s002280050622 10.1002/art.20375 10.2165/00003495-199958060-00010 10.1592/phco.26.6.868 10.1002/j.1552-4604.1987.tb03002.x 10.1007/s40265-017-0829-7 10.1001/jamaophthalmol.2014.3459 10.3899/jrheum.090153 10.1002/jcph.1350 10.1080/03009740510018723 10.1016/S2665-9913(20)30276-9 10.3899/jrheum.120922 10.1111/j.0954-6820.1982.tb01971.x 10.1111/cts.13152 10.1093/rheumatology/kei200 10.2165/00003495-200565130-00008 10.1093/rheumatology/35.5.453 10.1002/cpdd.870 10.1093/rheumatology/keab153 10.1021/acs.chemrestox.9b00141 10.1002/cpdd.71 10.1111/bcp.13329 10.1345/aph.1E012 10.1345/aph.1R542 10.1002/jcph.354 |
ContentType | Journal Article |
Copyright | Deutsche Gesellschaft für Rheumatologie e.V. Published by Springer Medizin Verlag GmbH. All rights reserved 2023 2023. Deutsche Gesellschaft für Rheumatologie e.V. Published by Springer Medizin Verlag GmbH. All rights reserved. |
Copyright_xml | – notice: Deutsche Gesellschaft für Rheumatologie e.V. Published by Springer Medizin Verlag GmbH. All rights reserved 2023 – notice: 2023. Deutsche Gesellschaft für Rheumatologie e.V. Published by Springer Medizin Verlag GmbH. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1007/s00393-023-01417-3 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Bewertung von Wechselwirkungen und Dosierungsempfehlungen von synthetischen DMARDs – Evidenz- und konsensbasierte Empfehlungen auf Basis einer systematischen Literatursuche |
DocumentTitle_FL | Bewertung von Wechselwirkungen und Dosierungsempfehlungen von synthetischen DMARDs – Evidenz- und konsensbasierte Empfehlungen auf Basis einer systematischen Literatursuche |
EISSN | 1435-1250 |
EndPage | 19 |
ExternalDocumentID | 10_1007_s00393_023_01417_3 37831190 |
Genre | Journal Article Review |
GroupedDBID | -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 1N0 1SB 203 29R 29~ 2J2 2JN 2JY 2KG 2LR 2P1 2VQ 2~H 30V 4.4 406 408 409 40D 40E 53G 5VS 67Z 6NX 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAFGU AAHNG AAIAL AAJKR AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACSNA ACTTH ACVWB ACZOJ ADHHG ADHIR ADINQ ADKNI ADKPE ADOXG ADTPH ADURQ ADYFF ADZKW AEBTG AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFLOW AFNRJ AFQWF AFWTZ AFZKB AGDGC AGGBP AGJBK AGMZJ AGQEE AGQMX AGWIL AGWZB AGYKE AHACP AHAVH AHBYD AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BGNMA CAG COF CSCUP DARCH DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV LAS LLZTM M4Y MA- N2Q N9A NB0 NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM P2P P9S PF0 PT4 QOR QOS R89 R9I RIG ROL RPX RRX RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 ZGI ZMTXR ZOVNA AACDK AAJBT AASML AAYZH ABAKF ACAOD ACDTI AEFQL AEMSY AIGIU CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c298t-8b8ca5aaf5837f2ff9e6ae3aac3c3d085ff3aeba0f1f1090d8c7eee8b54faa823 |
IEDL.DBID | AGYKE |
ISSN | 0340-1855 1435-1250 |
IngestDate | Thu Sep 12 00:39:57 EDT 2024 Thu Sep 12 19:29:03 EDT 2024 Sun Oct 13 09:52:46 EDT 2024 Wed Feb 21 01:30:03 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Keywords | Rheumatoide Arthritis Janus kinase inhibitors Rheumatoid arthritis Drug interactions Pharmakologie Arzneimittelinteraktionen Pharmacology Januskinaseinhibitoren Disease-modifying antirheumatic drugs |
Language | English |
License | 2023. Deutsche Gesellschaft für Rheumatologie e.V. Published by Springer Medizin Verlag GmbH. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c298t-8b8ca5aaf5837f2ff9e6ae3aac3c3d085ff3aeba0f1f1090d8c7eee8b54faa823 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-4 content type line 23 ObjectType-Undefined-3 |
PMID | 37831190 |
PQID | 2877389769 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2877389769 crossref_primary_10_1007_s00393_023_01417_3 pubmed_primary_37831190 springer_journals_10_1007_s00393_023_01417_3 |
PublicationCentury | 2000 |
PublicationDate | 2024-02-01 |
PublicationDateYYYYMMDD | 2024-02-01 |
PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Heidelberg |
PublicationPlace_xml | – name: Heidelberg – name: Germany |
PublicationTitle | Zeitschrift für Rheumatologie |
PublicationTitleAbbrev | Z Rheumatol |
PublicationTitleAlternate | Z Rheumatol |
PublicationYear | 2024 |
Publisher | Springer Medizin |
Publisher_xml | – name: Springer Medizin |
References | Patil, Parker, Rawcliffe (CR19) 2014; 33 Fiehn, Müller-Ladner, Rau (CR2) 2016 Melles, Marmor (CR26) 2014; 132 Burmester, Mariette, Montecucco (CR37) 2007; 66 Begley, Anderson, Watkins (CR60) 2021; 10 Sathi, Ackah, Dawson (CR16) 2006; 45 Lane, Weaver, Kostka (CR25) 2020; 2 Behrens, Koehm, Rossmanith (CR39) 2021; 60 Veeravalli, Dash, Thomas (CR47) 2020; 43 Anderson, Nelson, Gong (CR55) 2022; 11 Russo, Wiese, Smith (CR43) 2013; 47 Kwon, Lee, Kim (CR5) 2018; 37 Homann, Bantel, Jobski (CR17) 2019; 126 Svanström, Lund, Melbye, Pasternak (CR6) 2018; 27 Meng, Anderson, Nelson (CR52) 2022; 88 Chonlahan, Halloran, Hammonds (CR35) 2006; 26 Shi, Chen, Lee (CR48) 2014; 54 Mohamed, Jungerwirth, Asatryan (CR57) 2017; 83 Lim, Pande (CR34) 2002; 325 Du Cheyron, Debruyne, Lobbedez (CR32) 1999; 55 Hsueh, Anderson, Shen (CR54) 2022; 15 Mogul, Corsi, McAuliffe (CR49) 2019; 53 Namour, Desrivot, Van der Aa (CR56) 2016; 10 Gupta, Chow, Wang (CR45) 2014; 3 Jansen, van der Heijden, Oerlemans (CR30) 2004; 50 Lim, Gaffney, Scott (CR3) 2005; 44 Bredemeier, Ranza, Kakehasi (CR13) 2021; 48 Juhl, Summers, Guillory (CR29) 1976; 20 Bologna, Viu, Jorgensen (CR18) 1996; 35 Iwamoto, Homma, Asano (CR41) 2005; 34 Menon, Riese, Wang (CR59) 2016; 5 Karim, Tolbert, Hunt (CR9) 1999; 12 Choi, Koo, Kim (CR24) 2021; 11 Mohamed, Camp, Jiang (CR58) 2016; 55 Quach, Chang, Brophy (CR14) 2017; 56 Dhillon, Keam (CR53) 2020; 80 Narváez, Díaz-Torné, Ruiz (CR38) 2011; 41 Mohamed, Trueman, Feng (CR61) 2019; 59 Furst (CR21) 1996; 5 Ahern, Booth, Loxton (CR7) 1988; 15 Leden (CR22) 1982; 211 Posada, Cannady, Payne (CR50) 2017; 10 Bird, Griffiths, Tymms (CR11) 2013; 40 Ette, Brown-Awala, Essien (CR23) 1987; 27 Rutanen, Kononoff, Arstila (CR36) 2014; 43 Bressolle, Bologna, Kinowski (CR20) 1989; 57 Bergner, Peters, Schmitt (CR42) 2013; 32 Filkova, Carvalho, Norton (CR1) 2017; 44 Payne, Zhang, Shahri (CR62) 2015; 74 Beaman, Hackett, Luxton (CR40) 2002; 36 Schwartz, Agrawal, Wong (CR8) 2009; 49 Vanhoof, Landewe, Van Wijngaerden (CR10) 2003; 62 Plosker, Croom (CR28) 2005; 65 Al-Salama, Scott (CR51) 2018; 78 Chan, Sanders, Du (CR12) 2004; 38 Basin, Escalante, Beardmore (CR15) 1991; 18 Guo, Li, Li (CR46) 2019; 32 Fiehn, Ness, Weseloh (CR27) 2019; 79 Prakash, Jarvis (CR33) 1999; 58 Bourré-Tessier, Haraoui (CR4) 2010; 37 Das, Eastwood (CR31) 1973; 18 Scott (CR44) 2017; 77 H Svanström (1417_CR6) 2018; 27 J Vanhoof (1417_CR10) 2003; 62 P Patil (1417_CR19) 2014; 33 F Behrens (1417_CR39) 2021; 60 LT Quach (1417_CR14) 2017; 56 BJ Choi (1417_CR24) 2021; 11 OC Kwon (1417_CR5) 2018; 37 J Narváez (1417_CR38) 2011; 41 GR Burmester (1417_CR37) 2007; 66 LJ Scott (1417_CR44) 2017; 77 ZT Al-Salama (1417_CR51) 2018; 78 C Payne (1417_CR62) 2015; 74 N Sathi (1417_CR16) 2006; 45 C Bologna (1417_CR18) 1996; 35 M Iwamoto (1417_CR41) 2005; 34 F Namour (1417_CR56) 2016; 10 G Jansen (1417_CR30) 2004; 50 JG Shi (1417_CR48) 2014; 54 KM Das (1417_CR31) 1973; 18 J Chonlahan (1417_CR35) 2006; 26 M Ahern (1417_CR7) 1988; 15 PA Russo (1417_CR43) 2013; 47 R Bergner (1417_CR42) 2013; 32 C Fiehn (1417_CR27) 2019; 79 MF Mohamed (1417_CR58) 2016; 55 A Karim (1417_CR9) 1999; 12 A Mogul (1417_CR49) 2019; 53 RP Juhl (1417_CR29) 1976; 20 A Prakash (1417_CR33) 1999; 58 P Bird (1417_CR11) 2013; 40 EI Ette (1417_CR23) 1987; 27 MF Mohamed (1417_CR57) 2017; 83 S Menon (1417_CR59) 2016; 5 C Fiehn (1417_CR2) 2016 GL Plosker (1417_CR28) 2005; 65 V Lim (1417_CR34) 2002; 325 F Homann (1417_CR17) 2019; 126 P Gupta (1417_CR45) 2014; 3 DE Furst (1417_CR21) 1996; 5 I Leden (1417_CR22) 1982; 211 R Begley (1417_CR60) 2021; 10 D Du Cheyron (1417_CR32) 1999; 55 K Anderson (1417_CR55) 2022; 11 MF Mohamed (1417_CR61) 2019; 59 JI Schwartz (1417_CR8) 2009; 49 J Bourré-Tessier (1417_CR4) 2010; 37 RB Melles (1417_CR26) 2014; 132 JCE Lane (1417_CR25) 2020; 2 MM Posada (1417_CR50) 2017; 10 J Rutanen (1417_CR36) 2014; 43 J Chan (1417_CR12) 2004; 38 X Guo (1417_CR46) 2019; 32 M Bredemeier (1417_CR13) 2021; 48 JM Beaman (1417_CR40) 2002; 36 A Meng (1417_CR52) 2022; 88 M Filkova (1417_CR1) 2017; 44 KS Basin (1417_CR15) 1991; 18 AY Lim (1417_CR3) 2005; 44 V Veeravalli (1417_CR47) 2020; 43 S Dhillon (1417_CR53) 2020; 80 CH Hsueh (1417_CR54) 2022; 15 F Bressolle (1417_CR20) 1989; 57 |
References_xml | – volume: 33 start-page: 403 issue: 3 year: 2014 end-page: 407 ident: CR19 article-title: Methotrexate-induced nausea and vomiting in adolescent and young adult patients publication-title: Clin Rheumatol doi: 10.1007/s10067-013-2389-x contributor: fullname: Rawcliffe – volume: 325 start-page: 1333 issue: 7376 year: 2002 ident: CR34 article-title: Leflunomide can potentiate the anticoagulant effect of warfarin publication-title: BMJ doi: 10.1136/bmj.325.7376.1333 contributor: fullname: Pande – volume: 66 start-page: 732 issue: 6 year: 2007 end-page: 739 ident: CR37 article-title: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the research in active rheumatoid arthritis (react) trial publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.066761 contributor: fullname: Montecucco – volume: 53 start-page: 947 year: 2019 end-page: 953 ident: CR49 article-title: Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis publication-title: Ann Pharmacother doi: 10.1177/1060028019839650 contributor: fullname: McAuliffe – volume: 10 start-page: 38 year: 2016 end-page: 48 ident: CR56 article-title: Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions publication-title: Drug Metab Lett doi: 10.2174/1872312810666151223103353 contributor: fullname: Van der Aa – volume: 15 start-page: 1356 issue: 9 year: 1988 end-page: 1360 ident: CR7 article-title: Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? publication-title: J Rheumatol contributor: fullname: Loxton – volume: 79 start-page: 186 issue: 2 year: 2019 end-page: 194 ident: CR27 article-title: Sicherheitsmanagement der Therapie mit Antimalariamitteln in der Rheumatologie. Interdisziplinäre Empfehlungen auf der Basis einer systematischen Literaturrecherche publication-title: Z Rheumatol doi: 10.1007/s00393-020-00751-0 contributor: fullname: Weseloh – volume: 49 start-page: 1202 issue: 10 year: 2009 end-page: 1209 ident: CR8 article-title: Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis publication-title: J Clin Pharmacol doi: 10.1177/0091270009338939 contributor: fullname: Wong – volume: 18 start-page: 609 issue: 4 year: 1991 end-page: 610 ident: CR15 article-title: Severe pancytopenia in a patient taking low dose methotrexate and probenecid publication-title: J Rheumatol contributor: fullname: Beardmore – volume: 126 start-page: 116 year: 2019 end-page: 125 ident: CR17 article-title: Agranulocytosis attributed to metamizole: an analysis of spontaneous reports in EudraVigilance 1985–2017 publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/bcpt.13310 contributor: fullname: Jobski – volume: 36 start-page: 75 issue: 1 year: 2002 end-page: 77 ident: CR40 article-title: Effect of hemodialysis on leflunomide plasma concentrations publication-title: Ann Pharmacother doi: 10.1345/aph.1A127 contributor: fullname: Luxton – volume: 44 start-page: 1051 issue: 8 year: 2005 end-page: 1055 ident: CR3 article-title: Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years publication-title: Rheumatology doi: 10.1093/rheumatology/keh685 contributor: fullname: Scott – volume: 48 start-page: 1519 issue: 10 year: 2021 end-page: 1527 ident: CR13 article-title: Safety of the methotrexate-leflunomide combination in rheumatoid arthritis: results of a multicentric, registry-based, cohort study (biobadabrasil) publication-title: J Rheumatol doi: 10.3899/jrheum.201248 contributor: fullname: Kakehasi – volume: 12 start-page: 2539 year: 1999 end-page: 2543 ident: CR9 article-title: Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis publication-title: J Rheumatol contributor: fullname: Hunt – volume: 41 start-page: 401 issue: 3 year: 2011 end-page: 405 ident: CR38 article-title: Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2011.06.005 contributor: fullname: Ruiz – volume: 5 start-page: 336 year: 2016 end-page: 342 ident: CR59 article-title: Evaluation of the effect of tofacitinib on the pharmacokinetics of oral contraceptive steroids in healthy female volunteers publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.270 contributor: fullname: Wang – volume: 18 start-page: 45 year: 1973 end-page: 50 ident: CR31 article-title: Effect of iron and calcium on salicylazosulphapyridine metabolism publication-title: Scott Med J doi: 10.1177/003693307301800203 contributor: fullname: Eastwood – volume: 44 start-page: 1786 year: 2017 end-page: 1179 ident: CR1 article-title: Polypharmacy and unplanned hospitalizations in patients with rheumatoid arthritis publication-title: J Rheumatol doi: 10.3899/jrheum.160818 contributor: fullname: Norton – volume: 43 start-page: 254 issue: 3 year: 2014 end-page: 258 ident: CR36 article-title: Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy publication-title: Scand J Rheumatol doi: 10.3109/03009742.2013.868511 contributor: fullname: Arstila – volume: 37 start-page: 3215 issue: 12 year: 2018 end-page: 3220 ident: CR5 article-title: Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole publication-title: Clin Rheumatol doi: 10.1007/s10067-018-4005-6 contributor: fullname: Kim – volume: 43 start-page: 711 year: 2020 end-page: 725 ident: CR47 article-title: Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved Janus Kinase inhibitors for rheumatoid arthritis treatment publication-title: Drug Saf doi: 10.1007/s40264-020-00938-z contributor: fullname: Thomas – volume: 80 start-page: 1987 year: 2020 end-page: 1997 ident: CR53 article-title: Filgotinib: first approval publication-title: Drugs doi: 10.1007/s40265-020-01439-0 contributor: fullname: Keam – volume: 57 start-page: 110 year: 1989 end-page: 113 ident: CR20 article-title: Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients publication-title: Ann Rheum Dis doi: 10.1136/ard.57.2.110 contributor: fullname: Kinowski – volume: 27 start-page: 885 issue: 8 year: 2018 end-page: 893 ident: CR6 article-title: Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4555 contributor: fullname: Pasternak – volume: 32 start-page: 267 issue: 2 year: 2013 end-page: 270 ident: CR42 article-title: Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic study publication-title: Clin Rheumatol doi: 10.1007/s10067-012-2122-1 contributor: fullname: Schmitt – volume: 5 start-page: S11 issue: 1 year: 1996 end-page: 5 ident: CR21 article-title: Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases publication-title: Lupus doi: 10.1177/0961203396005001041 contributor: fullname: Furst – volume: 10 start-page: 509 issue: 6 year: 2017 end-page: 519 ident: CR50 article-title: Prediction of transporter-mediated drug-drug interactions for baricitinib publication-title: Clin Transl Sci doi: 10.1111/cts.12486 contributor: fullname: Payne – volume: 56 start-page: 378 issue: 3 year: 2017 end-page: 383 ident: CR14 article-title: Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events publication-title: Rheumatology contributor: fullname: Brophy – volume: 55 start-page: 1547 issue: 12 year: 2016 end-page: 1558 ident: CR58 article-title: Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0419-y contributor: fullname: Jiang – volume: 78 start-page: 761 year: 2018 end-page: 772 ident: CR51 article-title: Baricitinib: a review in rheumatoid arthritis publication-title: Drugs doi: 10.1007/s40265-018-0908-4 contributor: fullname: Scott – volume: 11 start-page: 235 year: 2022 end-page: 245 ident: CR55 article-title: Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.1015 contributor: fullname: Gong – volume: 11 start-page: 6918 year: 2021 ident: CR24 article-title: Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice publication-title: Nat Sci Rep contributor: fullname: Kim – volume: 88 start-page: 3211 year: 2022 end-page: 3221 ident: CR52 article-title: Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.15239 contributor: fullname: Nelson – volume: 62 start-page: 1241 issue: 12 year: 2003 end-page: 1242 ident: CR10 article-title: High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors publication-title: Ann Rheum Dis doi: 10.1136/ard.2002.004598 contributor: fullname: Van Wijngaerden – volume: 74 start-page: 1063 year: 2015 end-page: 1063 ident: CR62 article-title: AB0492 evaluation of potential drug-drug interactions with baricitinib publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-eular.1627 contributor: fullname: Shahri – volume: 20 start-page: 387 year: 1976 end-page: 394 ident: CR29 article-title: Effect of sulfasalazine on digoxin bioavailability publication-title: Clin Pharmacol Ther doi: 10.1002/cpt1976204387 contributor: fullname: Guillory – volume: 55 start-page: 227 year: 1999 end-page: 228 ident: CR32 article-title: Effect of sulfasalazine on cyclosporin blood concentration publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050622 contributor: fullname: Lobbedez – volume: 50 start-page: 2130 year: 2004 end-page: 2139 ident: CR30 article-title: Sulfasalazine is a potent inhibitor of the reduced folate carrier—implications for combination therapies with methotrexate in rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.20375 contributor: fullname: Oerlemans – start-page: 23 year: 2016 end-page: 29 ident: CR2 article-title: Pharmakologie von Methotrexat publication-title: Methotrexat bei Autoimmunerkrankungen – moderne Therapiekonzepte in der Rheumatologie, Dermatologie und Gastroenterologie contributor: fullname: Rau – volume: 58 start-page: 1137 issue: 6 year: 1999 end-page: 1164 ident: CR33 article-title: Leflunomid: a review of its use in active rheumatoid arthritis publication-title: Drugs doi: 10.2165/00003495-199958060-00010 contributor: fullname: Jarvis – volume: 26 start-page: 868 issue: 6 year: 2006 end-page: 871 ident: CR35 article-title: Leflunomide and warfarin interaction: case report and review of the literature publication-title: Pharmacotherapy doi: 10.1592/phco.26.6.868 contributor: fullname: Hammonds – volume: 27 start-page: 813 year: 1987 end-page: 816 ident: CR23 article-title: Chloroquine elimination in humans: effect of low-dose cimetidine publication-title: J Clin Pharmacol doi: 10.1002/j.1552-4604.1987.tb03002.x contributor: fullname: Essien – volume: 77 start-page: 1865 year: 2017 end-page: 1879 ident: CR44 article-title: Tofacitinib: a review in rheumatoid arthritis publication-title: Drugs doi: 10.1007/s40265-017-0829-7 contributor: fullname: Scott – volume: 132 start-page: 1453 year: 2014 end-page: 1460 ident: CR26 article-title: The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2014.3459 contributor: fullname: Marmor – volume: 37 start-page: 1416 issue: 7 year: 2010 end-page: 1421 ident: CR4 article-title: Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review publication-title: J Rheumatol doi: 10.3899/jrheum.090153 contributor: fullname: Haraoui – volume: 59 start-page: 510 year: 2019 end-page: 516 ident: CR61 article-title: The JAK1 inhibitor upadacitinib has no effect on the pharmacokinetics of levonorgestrel and ethinylestradiol: a study in healthy female subjects publication-title: J Clin Pharmacol doi: 10.1002/jcph.1350 contributor: fullname: Feng – volume: 34 start-page: 410 issue: 5 year: 2005 end-page: 411 ident: CR41 article-title: Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis publication-title: Scand J Rheumatol doi: 10.1080/03009740510018723 contributor: fullname: Asano – volume: 2 start-page: e698 year: 2020 end-page: 711 ident: CR25 article-title: Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(20)30276-9 contributor: fullname: Kostka – volume: 40 start-page: 228 issue: 3 year: 2013 end-page: 235 ident: CR11 article-title: The SMILE study—safety of methotrexate in combination with leflunomide in rheumatoid arthritis publication-title: J Rheumatol doi: 10.3899/jrheum.120922 contributor: fullname: Tymms – volume: 211 start-page: 411 year: 1982 end-page: 412 ident: CR22 article-title: Digoxin-hydroxychloroquine interaction publication-title: Acta Med Scand doi: 10.1111/j.0954-6820.1982.tb01971.x contributor: fullname: Leden – volume: 15 start-page: 361 year: 2022 end-page: 370 ident: CR54 article-title: Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects publication-title: Clin Transl Sci doi: 10.1111/cts.13152 contributor: fullname: Shen – volume: 45 start-page: 361 issue: 3 year: 2006 end-page: 362 ident: CR16 article-title: Methotrexate induced neutropenia associated with coprescription of penicillins: serious and under-reported? publication-title: Rheumatology doi: 10.1093/rheumatology/kei200 contributor: fullname: Dawson – volume: 65 start-page: 1825 year: 2005 end-page: 1849 ident: CR28 article-title: Sulfasalazine publication-title: Drugs doi: 10.2165/00003495-200565130-00008 contributor: fullname: Croom – volume: 35 start-page: 453 issue: 5 year: 1996 end-page: 457 ident: CR18 article-title: Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis publication-title: Br J Rheumatol doi: 10.1093/rheumatology/35.5.453 contributor: fullname: Jorgensen – volume: 10 start-page: 376 year: 2021 end-page: 383 ident: CR60 article-title: Lack of drug-drug interaction between filgotinib, a selective JAK1 inhibitor, and oral hormonal contraceptives levonorgestrel/ethinyl estradiol in healthy volunteers publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.870 contributor: fullname: Watkins – volume: 60 start-page: 5318 issue: 11 year: 2021 end-page: 5328 ident: CR39 article-title: Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study) publication-title: Rheumatology doi: 10.1093/rheumatology/keab153 contributor: fullname: Rossmanith – volume: 32 start-page: 1791 year: 2019 end-page: 1800 ident: CR46 article-title: Tofacitinib is a mechanism-based inactivator of cytochrome P450 3A4 publication-title: Chem Res Toxicol doi: 10.1021/acs.chemrestox.9b00141 contributor: fullname: Li – volume: 3 start-page: 72 year: 2014 end-page: 77 ident: CR45 article-title: Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.71 contributor: fullname: Wang – volume: 83 start-page: 2242 year: 2017 end-page: 2248 ident: CR57 article-title: Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13329 contributor: fullname: Asatryan – volume: 38 start-page: 1206 issue: 7–8 year: 2004 end-page: 1211 ident: CR12 article-title: Leflunomide-associated pancytopenia with or without methotrexate publication-title: Ann Pharmacother doi: 10.1345/aph.1E012 contributor: fullname: Du – volume: 47 start-page: e15 year: 2013 ident: CR43 article-title: Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study publication-title: Ann Pharmacother doi: 10.1345/aph.1R542 contributor: fullname: Smith – volume: 54 start-page: 1354 year: 2014 end-page: 1361 ident: CR48 article-title: The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers publication-title: J Clin Pharmacol doi: 10.1002/jcph.354 contributor: fullname: Lee – volume: 77 start-page: 1865 year: 2017 ident: 1417_CR44 publication-title: Drugs doi: 10.1007/s40265-017-0829-7 contributor: fullname: LJ Scott – volume: 74 start-page: 1063 year: 2015 ident: 1417_CR62 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-eular.1627 contributor: fullname: C Payne – volume: 11 start-page: 235 year: 2022 ident: 1417_CR55 publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.1015 contributor: fullname: K Anderson – volume: 83 start-page: 2242 year: 2017 ident: 1417_CR57 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13329 contributor: fullname: MF Mohamed – volume: 2 start-page: e698 year: 2020 ident: 1417_CR25 publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(20)30276-9 contributor: fullname: JCE Lane – volume: 27 start-page: 885 issue: 8 year: 2018 ident: 1417_CR6 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4555 contributor: fullname: H Svanström – volume: 59 start-page: 510 year: 2019 ident: 1417_CR61 publication-title: J Clin Pharmacol doi: 10.1002/jcph.1350 contributor: fullname: MF Mohamed – volume: 41 start-page: 401 issue: 3 year: 2011 ident: 1417_CR38 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2011.06.005 contributor: fullname: J Narváez – volume: 60 start-page: 5318 issue: 11 year: 2021 ident: 1417_CR39 publication-title: Rheumatology doi: 10.1093/rheumatology/keab153 contributor: fullname: F Behrens – volume: 5 start-page: S11 issue: 1 year: 1996 ident: 1417_CR21 publication-title: Lupus doi: 10.1177/0961203396005001041 contributor: fullname: DE Furst – volume: 5 start-page: 336 year: 2016 ident: 1417_CR59 publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.270 contributor: fullname: S Menon – volume: 62 start-page: 1241 issue: 12 year: 2003 ident: 1417_CR10 publication-title: Ann Rheum Dis doi: 10.1136/ard.2002.004598 contributor: fullname: J Vanhoof – volume: 10 start-page: 376 year: 2021 ident: 1417_CR60 publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.870 contributor: fullname: R Begley – volume: 44 start-page: 1786 year: 2017 ident: 1417_CR1 publication-title: J Rheumatol doi: 10.3899/jrheum.160818 contributor: fullname: M Filkova – volume: 211 start-page: 411 year: 1982 ident: 1417_CR22 publication-title: Acta Med Scand doi: 10.1111/j.0954-6820.1982.tb01971.x contributor: fullname: I Leden – volume: 20 start-page: 387 year: 1976 ident: 1417_CR29 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt1976204387 contributor: fullname: RP Juhl – volume: 26 start-page: 868 issue: 6 year: 2006 ident: 1417_CR35 publication-title: Pharmacotherapy doi: 10.1592/phco.26.6.868 contributor: fullname: J Chonlahan – volume: 34 start-page: 410 issue: 5 year: 2005 ident: 1417_CR41 publication-title: Scand J Rheumatol doi: 10.1080/03009740510018723 contributor: fullname: M Iwamoto – volume: 10 start-page: 38 year: 2016 ident: 1417_CR56 publication-title: Drug Metab Lett doi: 10.2174/1872312810666151223103353 contributor: fullname: F Namour – volume: 56 start-page: 378 issue: 3 year: 2017 ident: 1417_CR14 publication-title: Rheumatology contributor: fullname: LT Quach – volume: 45 start-page: 361 issue: 3 year: 2006 ident: 1417_CR16 publication-title: Rheumatology doi: 10.1093/rheumatology/kei200 contributor: fullname: N Sathi – volume: 11 start-page: 6918 year: 2021 ident: 1417_CR24 publication-title: Nat Sci Rep contributor: fullname: BJ Choi – volume: 88 start-page: 3211 year: 2022 ident: 1417_CR52 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.15239 contributor: fullname: A Meng – volume: 80 start-page: 1987 year: 2020 ident: 1417_CR53 publication-title: Drugs doi: 10.1007/s40265-020-01439-0 contributor: fullname: S Dhillon – volume: 37 start-page: 3215 issue: 12 year: 2018 ident: 1417_CR5 publication-title: Clin Rheumatol doi: 10.1007/s10067-018-4005-6 contributor: fullname: OC Kwon – volume: 35 start-page: 453 issue: 5 year: 1996 ident: 1417_CR18 publication-title: Br J Rheumatol doi: 10.1093/rheumatology/35.5.453 contributor: fullname: C Bologna – volume: 55 start-page: 227 year: 1999 ident: 1417_CR32 publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050622 contributor: fullname: D Du Cheyron – volume: 325 start-page: 1333 issue: 7376 year: 2002 ident: 1417_CR34 publication-title: BMJ doi: 10.1136/bmj.325.7376.1333 contributor: fullname: V Lim – volume: 65 start-page: 1825 year: 2005 ident: 1417_CR28 publication-title: Drugs doi: 10.2165/00003495-200565130-00008 contributor: fullname: GL Plosker – volume: 43 start-page: 254 issue: 3 year: 2014 ident: 1417_CR36 publication-title: Scand J Rheumatol doi: 10.3109/03009742.2013.868511 contributor: fullname: J Rutanen – volume: 49 start-page: 1202 issue: 10 year: 2009 ident: 1417_CR8 publication-title: J Clin Pharmacol doi: 10.1177/0091270009338939 contributor: fullname: JI Schwartz – volume: 79 start-page: 186 issue: 2 year: 2019 ident: 1417_CR27 publication-title: Z Rheumatol doi: 10.1007/s00393-020-00751-0 contributor: fullname: C Fiehn – volume: 55 start-page: 1547 issue: 12 year: 2016 ident: 1417_CR58 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0419-y contributor: fullname: MF Mohamed – volume: 53 start-page: 947 year: 2019 ident: 1417_CR49 publication-title: Ann Pharmacother doi: 10.1177/1060028019839650 contributor: fullname: A Mogul – volume: 36 start-page: 75 issue: 1 year: 2002 ident: 1417_CR40 publication-title: Ann Pharmacother doi: 10.1345/aph.1A127 contributor: fullname: JM Beaman – volume: 48 start-page: 1519 issue: 10 year: 2021 ident: 1417_CR13 publication-title: J Rheumatol doi: 10.3899/jrheum.201248 contributor: fullname: M Bredemeier – volume: 126 start-page: 116 year: 2019 ident: 1417_CR17 publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/bcpt.13310 contributor: fullname: F Homann – volume: 132 start-page: 1453 year: 2014 ident: 1417_CR26 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2014.3459 contributor: fullname: RB Melles – volume: 15 start-page: 1356 issue: 9 year: 1988 ident: 1417_CR7 publication-title: J Rheumatol contributor: fullname: M Ahern – volume: 38 start-page: 1206 issue: 7–8 year: 2004 ident: 1417_CR12 publication-title: Ann Pharmacother doi: 10.1345/aph.1E012 contributor: fullname: J Chan – volume: 58 start-page: 1137 issue: 6 year: 1999 ident: 1417_CR33 publication-title: Drugs doi: 10.2165/00003495-199958060-00010 contributor: fullname: A Prakash – volume: 44 start-page: 1051 issue: 8 year: 2005 ident: 1417_CR3 publication-title: Rheumatology doi: 10.1093/rheumatology/keh685 contributor: fullname: AY Lim – volume: 57 start-page: 110 year: 1989 ident: 1417_CR20 publication-title: Ann Rheum Dis doi: 10.1136/ard.57.2.110 contributor: fullname: F Bressolle – start-page: 23 volume-title: Methotrexat bei Autoimmunerkrankungen – moderne Therapiekonzepte in der Rheumatologie, Dermatologie und Gastroenterologie year: 2016 ident: 1417_CR2 contributor: fullname: C Fiehn – volume: 27 start-page: 813 year: 1987 ident: 1417_CR23 publication-title: J Clin Pharmacol doi: 10.1002/j.1552-4604.1987.tb03002.x contributor: fullname: EI Ette – volume: 12 start-page: 2539 year: 1999 ident: 1417_CR9 publication-title: J Rheumatol contributor: fullname: A Karim – volume: 3 start-page: 72 year: 2014 ident: 1417_CR45 publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.71 contributor: fullname: P Gupta – volume: 78 start-page: 761 year: 2018 ident: 1417_CR51 publication-title: Drugs doi: 10.1007/s40265-018-0908-4 contributor: fullname: ZT Al-Salama – volume: 15 start-page: 361 year: 2022 ident: 1417_CR54 publication-title: Clin Transl Sci doi: 10.1111/cts.13152 contributor: fullname: CH Hsueh – volume: 47 start-page: e15 year: 2013 ident: 1417_CR43 publication-title: Ann Pharmacother doi: 10.1345/aph.1R542 contributor: fullname: PA Russo – volume: 32 start-page: 1791 year: 2019 ident: 1417_CR46 publication-title: Chem Res Toxicol doi: 10.1021/acs.chemrestox.9b00141 contributor: fullname: X Guo – volume: 40 start-page: 228 issue: 3 year: 2013 ident: 1417_CR11 publication-title: J Rheumatol doi: 10.3899/jrheum.120922 contributor: fullname: P Bird – volume: 18 start-page: 45 year: 1973 ident: 1417_CR31 publication-title: Scott Med J doi: 10.1177/003693307301800203 contributor: fullname: KM Das – volume: 66 start-page: 732 issue: 6 year: 2007 ident: 1417_CR37 publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.066761 contributor: fullname: GR Burmester – volume: 10 start-page: 509 issue: 6 year: 2017 ident: 1417_CR50 publication-title: Clin Transl Sci doi: 10.1111/cts.12486 contributor: fullname: MM Posada – volume: 37 start-page: 1416 issue: 7 year: 2010 ident: 1417_CR4 publication-title: J Rheumatol doi: 10.3899/jrheum.090153 contributor: fullname: J Bourré-Tessier – volume: 33 start-page: 403 issue: 3 year: 2014 ident: 1417_CR19 publication-title: Clin Rheumatol doi: 10.1007/s10067-013-2389-x contributor: fullname: P Patil – volume: 32 start-page: 267 issue: 2 year: 2013 ident: 1417_CR42 publication-title: Clin Rheumatol doi: 10.1007/s10067-012-2122-1 contributor: fullname: R Bergner – volume: 50 start-page: 2130 year: 2004 ident: 1417_CR30 publication-title: Arthritis Rheum doi: 10.1002/art.20375 contributor: fullname: G Jansen – volume: 18 start-page: 609 issue: 4 year: 1991 ident: 1417_CR15 publication-title: J Rheumatol contributor: fullname: KS Basin – volume: 43 start-page: 711 year: 2020 ident: 1417_CR47 publication-title: Drug Saf doi: 10.1007/s40264-020-00938-z contributor: fullname: V Veeravalli – volume: 54 start-page: 1354 year: 2014 ident: 1417_CR48 publication-title: J Clin Pharmacol doi: 10.1002/jcph.354 contributor: fullname: JG Shi |
SSID | ssj0014644 |
Score | 2.3757672 |
SecondaryResourceType | review_article |
Snippet | Conventional synthetic (cs) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) have potential interactions with a multitude of drugs.... Conventional synthetic (cs) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) have potential interactions with a multitude of drugs.... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 8 |
SubjectTerms | Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biological Products - therapeutic use Consensus Drug Interactions Drug Therapy, Combination Empfehlungen und Stellungnahmen von Fachgesellschaften Humans Immunology Internal Medicine Laboratory Medicine Medicine Medicine & Public Health Orthopedics Rheumatology |
Title | Assessment of interactions and dosage recommendations of synthetic DMARDs—Evidence-based and consensus-based recommendations based on a systematic literature search |
URI | https://link.springer.com/article/10.1007/s00393-023-01417-3 https://www.ncbi.nlm.nih.gov/pubmed/37831190 https://www.proquest.com/docview/2877389769/abstract/ |
Volume | 83 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NTtwwEB6VRap6AVpaWArIlbhRo93YSZxjxK9A20PFSvQUOY59oU0Q2T3AiYfgAbjxHjwKT9KxnQTBIiSuljNWPLbnG83MNwBb6NskikUFHagBp9y2NkFfhdMkybkZJLGMXTug0a_oaMyPz8Kzpzpul-zeRiTdQ93VurkqUoomhtrcRLwZczAfWsKvHsynh39O9rvgAY-4Z41yYcswbGplXpfy3B7NgMyZAKmzOweLcNpW7_h0k_Od6STfUdezZI7v-aUlWGhwKEn9wfkMH3T5BT6Omkj7MtynHWUnqQyxrBKXvgaiJrIsSFHZjDRi_el_OMl3Zqrt1PqqRFCJYsneKP29Vz_e3LatS6m1mYX7Xtks7rKe1s3YS0F-tCqJfLh7YpsmfzsWaOLv6FcYH-yf7h7RpqkDVUEiJlTkQslQShOia2wCYxIdSc2kVEyxAgGgMUzqXA7M0Nik0UKoWGst8pAbKUXAvkGvrEq9CsSgs8cMKlyrmIdqmCNa5LrI0YcMIqFFH7Zb1WYXnrsj61ia3d5nuPeZ2_uM9eFHq_0Mr5iNm8hSV9M6Q6cyRlwXR0kfVvyx6OSxWLAhgqo-_Gx1nDWvQP3GYmvvm_4dPgUIpny2-Dr0JpdTvYFgaJJvNod_E-bGQfofjSgFAg |
link.rule.ids | 315,786,790,27955,27956,41114,41556,42183,42625,52144,52267 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NTtwwEB7xI0EvVSk_3f5QI_UGlnZjJ3GOqwJaKMuhYiVuluPYJ0gQ3j1w4yH6AL31PfoofZKO7SSogCpxtZzJ4ctkvtHMfAPwBXObQrOsokM95JT71SaYq3BaFCW3wyJXeVgHND3PJjN-epletkNhrut270qS4U_dD7uFMVKKMYb65kR0jWVY9XrqvpFvloz72gHPeBSNClXLNG1HZZ638W84esIxn9RHQ9g5fgOvW75IxhHgDVgy9VtYm7YV8U34Ne6lNUljiVd_uI2zCo6ouiJV4zvHiM97r_FS3KDk_FV3VyP5Q7PkcDr-fuj-3P_oVoxSH9uq8Lz23da1W7j27LGheNrURP3--aAKTa56tWYSfWkLZsdHF18ntF2-QHVSiDkVpdAqVcqmmMLaxNrCZMowpTTTrEKiZi1TplRDO7K-ubMSOjfGiDLlVimRsG1YqZvavANiMSljFpExOuepHpXI6ripSsz1kkwYMYD9DgN5EzU2ZK-mHBCTiJgMiEk2gL0OJomu4OsbqjbNwklM_nLkX3lWDGAn4tfbY7lgIyQ_AzjoAJWtt7r_vOz9y65_hvXJxfRMnp2cf_sArxIkQLHD-yOszG8X5hMSmHm5G77Xv6rO6vI |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NTtwwEB6VrYS4IFr6s9AfI3FrLXZjJ3GOq25X9GdXVdWVuFmOY5-og8jugRsP0Qfore_RR-FJGNtJSkuFxNVyJofPo_lGM_MNwCHmNoVmWUVHesQp96tNMFfhtChKbkdFrvKwDmi-yI6X_ONJenJjij90u3clyTjT4FWa3OrorLJH_eBbGCmlGG-ob1REN9mAhz40-je-TCZ9HYFnPApIhQpmmrZjM_-38XdousU3b9VKQwia7cB2yx3JJIL9CB4Y9xg25211fBd-TXqZTVJb4pUgzuPcQkOUq0hV-y4y4nPg73gpblNq_NXmwiERRLNkOp98nTZXlz-6daPUx7kqfK9957Vr1k179q-heFo7on7__KMQTU575WYS_eoJLGfvv707pu0iBqqTQqyoKIVWqVI2xXTWJtYWJlOGKaWZZhWSNmuZMqUa2bH1jZ6V0LkxRpQpt0qJhD2FgaudeQ7EYoLGLCJjdM5TPS6R4XFTlZj3JZkwYghvOgzkWdTbkL2yckBMImIyICbZEA46mCS6ha91KGfqdSMxEcyRi-VZMYRnEb_eHssFGyMRGsLbDlDZem5zx8_27nf9NWx-mc7k5w-LT_uwlSAXis3eL2CwOl-bl8hlVuWr8FyvAQD67zc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+interactions+and+dosage+recommendations+of+synthetic+DMARDs%E2%80%94Evidence-based+and+consensus-based+recommendations+based+on+a%C2%A0systematic+literature+search&rft.jtitle=Zeitschrift+f%C3%BCr+Rheumatologie&rft.au=Fiehn%2C+C.&rft.au=Leipe%2C+J.&rft.au=Weseloh%2C+C.&rft.au=Bergner%2C+R.&rft.date=2024-02-01&rft.issn=0340-1855&rft.eissn=1435-1250&rft.volume=83&rft.issue=S1&rft.spage=8&rft.epage=19&rft_id=info:doi/10.1007%2Fs00393-023-01417-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00393_023_01417_3 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-1855&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-1855&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-1855&client=summon |